期刊
CLINICAL INFECTIOUS DISEASES
卷 54, 期 -, 页码 S16-S22出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir865
关键词
-
资金
- US Public Health Service [R01 AI063503, R21 AI082414]
- Henry Schueler 419 Foundation
- Astellas Pharma US
- Enzon
- Gilead
- Merck
- Pfizer
- NovaDigm Therapeutics
- Novartis
- Astellas Pharma US, Inc.
- Schering-Plough
- Enzon Pharmaceuticals
Mucormycosis is a life-threatening infection that occurs in patients who are immunocompromised because of diabetic ketoacidosis, neutropenia, organ transplantation, and/or increased serum levels of available iron. Because of the increasing prevalence of diabetes mellitus, cancer, and organ transplantation, the number of patients at risk for this deadly infection is increasing. Despite aggressive therapy, which includes disfiguring surgical debridement and frequently adjunctive toxic antifungal therapy, the overall mortality rate is high. New strategies to prevent and treat mucormycosis are urgently needed. Understanding the pathogenesis of mucormycosis and the host response to invading hyphae ultimately will provide targets for novel therapeutic interventions. In this supplement, we review the current knowledge about the virulence traits used by the most common etiologic agent of mucormycosis, Rhizopus oryzae. Because patients with elevated serum levels of available iron are uniquely susceptible to mucormycosis and these infections are highly angioinvasive, emphasis is placed on the ability of the organism to acquire iron from the host and on its interactions with endothelial cells lining blood vessels. Several promising therapeutic strategies in preclinical stages are identified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据